

AMENDMENTS TO THE SPECIFICATION

IN THE TITLE

Please amend the title as follows:

D¹ "METHOD-USE OF A SOLUBLE RECOMBINANT HUMAN CD40L PROTEIN FOR
INHIBITING AN IN VIVO ALLOIMMUNE RESPONSE".

IN THE DETAILED DESCRIPTION OF THE INVENTION

Please substitute the last paragraph beginning on page 11 and continuing on to page 12 with the following paragraph:

D² All SCID mice were exposed to 200 cGy of irradiation prior to reconstitution to enhance cellular engraftment. To deplete NK cells, some SCID mice were injected with 20 μ l of anti-asialoGM₁ antisera (Wako Pure Chemical Industries LTD, Dallas, TX) 1 day prior to reconstitution. One unit of whole blood was collected into standard collection bags containing CP2D (Citrate Phosphate Double Dextrose); following centrifugation at 4550 x g for 3.2 min and removal of the supernatant plasma, buffy coats were transferred into a satellite bag. To obtain human PBL, the buffy coat was layered onto a 1.077 g/L PercollTM (Pharmacia LKB, Baie d'Urfe, Quebec) gradient and separated by centrifugation (1200 x g for 30 min at 22°C). The PBL were washed three times with phosphate-buffered saline, pH 7.4 (PBS), adjusted to a concentration of 8×10^7 / ml in 80% FCS in RPMI-1640, and 0.5 ml injected into the peritoneal cavity of recipient SCID mice using a 27 guage needle.

IN THE ABSTRACT

Please add the following heading and abstract of the disclosure: